EdgarLookup

INTELLINETICS, INC. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that INTELLINETICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-71.5%
Profit Margin
Net income ÷ revenue
-10.8%
Return on Assets
Net income ÷ assets
0.52x
Debt-to-Equity
Total liabilities ÷ equity

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2018 Dec 31, 2017 $2.62M Apr 1, 2019
FY2011 Dec 31, 2011 $0 Jan 31, 2012
FY2011 Dec 31, 2010 $0 Jan 31, 2012

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $16.58M Mar 30, 2026
FY2025 Dec 31, 2024 $18.02M Mar 30, 2026
FY2024 Dec 31, 2023 $16.89M Mar 24, 2025
FY2023 Dec 31, 2022 $14.02M Mar 28, 2024
FY2022 Dec 31, 2021 $11.46M Mar 27, 2023
FY2021 Dec 31, 2020 $8.25M Mar 24, 2022
FY2020 Dec 31, 2019 $2.54M Mar 30, 2021
FY2019 Dec 31, 2018 $2.38M Mar 30, 2020
FY2018 Dec 31, 2017 $2.62M Apr 1, 2019

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $2.62M Apr 2, 2018
FY2017 Dec 31, 2016 $2.60M Apr 2, 2018
FY2016 Dec 31, 2015 $2.34M Mar 30, 2017
FY2015 Dec 31, 2014 $1.49M Mar 28, 2016
FY2014 Dec 31, 2013 $1.55M Mar 31, 2015
FY2013 Dec 31, 2012 $2.73M Mar 31, 2014
FY2012 Dec 31, 2011 $1.73M Apr 1, 2013

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $10.95M Mar 30, 2026
FY2025 Dec 31, 2024 $11.37M Mar 30, 2026
FY2024 Dec 31, 2023 $10.56M Mar 24, 2025
FY2023 Dec 31, 2022 $8.91M Mar 28, 2024
FY2022 Dec 31, 2021 $6.94M Mar 27, 2023
FY2021 Dec 31, 2020 $4.99M Mar 24, 2022
FY2020 Dec 31, 2019 $1.97M Mar 30, 2021
FY2019 Dec 31, 2018 $1.64M Mar 30, 2020
FY2018 Dec 31, 2017 $1.86M Apr 1, 2019
FY2017 Dec 31, 2016 $1.89M Apr 2, 2018

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($1.87M) Mar 30, 2026
FY2025 Dec 31, 2024 ($546.2K) Mar 30, 2026
FY2024 Dec 31, 2023 $519.3K Mar 24, 2025
FY2023 Dec 31, 2022 $24.0K Mar 28, 2024
FY2022 Dec 31, 2021 $1.36M Mar 27, 2023
FY2021 Dec 31, 2020 ($2.20M) Mar 24, 2022
FY2020 Dec 31, 2019 ($2.13M) Mar 30, 2021
FY2019 Dec 31, 2018 ($2.34M) Mar 30, 2020
FY2018 Dec 31, 2017 ($1.37M) Apr 1, 2019
FY2017 Dec 31, 2016 ($1.58M) Apr 2, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($1.79M) Mar 30, 2026
FY2025 Dec 31, 2024 ($173.5K) Mar 30, 2026
FY2024 Dec 31, 2023 $1.11M Mar 24, 2025
FY2023 Dec 31, 2022 $827.3K Mar 28, 2024
FY2022 Dec 31, 2021 $965.0K Mar 27, 2023
FY2021 Dec 31, 2020 ($2.04M) Mar 24, 2022
FY2020 Dec 31, 2019 ($1.15M) Mar 30, 2021
FY2019 Dec 31, 2018 ($1.47M) Mar 30, 2020
FY2018 Dec 31, 2017 ($1.17M) Apr 1, 2019
FY2017 Dec 31, 2016 ($1.37M) Apr 2, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2020 Dec 31, 2020 $293.1K Mar 30, 2021
FY2020 Dec 31, 2019 $467.4K Mar 30, 2021
FY2019 Dec 31, 2018 $359.8K Mar 30, 2020
FY2018 Dec 31, 2017 $412.4K Apr 1, 2019
FY2017 Dec 31, 2016 $386.3K Apr 2, 2018
FY2016 Dec 31, 2015 $498.0K Mar 30, 2017
FY2015 Dec 31, 2014 $407.7K Mar 28, 2016
FY2014 Dec 31, 2013 $285.8K Mar 31, 2015

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $933.9K Mar 30, 2026
FY2025 Dec 31, 2024 $3.86M Mar 30, 2026
FY2024 Dec 31, 2023 $784.7K Mar 24, 2025
FY2023 Dec 31, 2022 $1.99M Mar 28, 2024
FY2022 Dec 31, 2021 $1.39M Mar 27, 2023
FY2021 Dec 31, 2020 $125.0K Mar 24, 2022
FY2020 Dec 31, 2019 ($982.2K) Mar 30, 2021
FY2019 Dec 31, 2018 ($1.16M) Mar 30, 2020
FY2018 Dec 31, 2017 ($1.12M) Apr 1, 2019
FY2017 Dec 31, 2016 ($1.26M) Apr 2, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $354.4K Mar 30, 2026
FY2025 Dec 31, 2024 $439.2K Mar 30, 2026
FY2024 Dec 31, 2023 $111.2K Mar 24, 2025
FY2023 Dec 31, 2022 $201.0K Mar 28, 2024
FY2022 Dec 31, 2021 $552.2K Mar 27, 2023
FY2021 Dec 31, 2020 $76.9K Mar 24, 2022
FY2020 Dec 31, 2019 $5.5K Mar 30, 2021
FY2019 Dec 31, 2018 $3.4K Mar 30, 2020
FY2018 Dec 31, 2017 $12.6K Apr 1, 2019
FY2017 Dec 31, 2016 $6.9K Apr 2, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $17.31M Mar 30, 2026
FY2025 Dec 31, 2024 $18.57M Mar 30, 2026
FY2024 Dec 31, 2023 $19.03M Mar 24, 2025
FY2023 Dec 31, 2022 $19.94M Mar 28, 2024
FY2022 Dec 31, 2021 $11.96M Mar 27, 2023
FY2021 Dec 31, 2020 $10.34M Mar 24, 2022
FY2020 Dec 31, 2019 $986.6K Mar 30, 2021
FY2019 Dec 31, 2018 $1.41M Mar 30, 2020
FY2018 Dec 31, 2017 $1.61M Apr 1, 2019
FY2017 Dec 31, 2016 $1.13M Apr 2, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $5.92M Mar 30, 2026
FY2025 Dec 31, 2024 $7.94M Mar 30, 2026
FY2024 Dec 31, 2023 $9.28M Mar 24, 2025
FY2023 Dec 31, 2022 $11.37M Mar 28, 2024
FY2022 Dec 31, 2021 $9.30M Mar 27, 2023
FY2021 Dec 31, 2020 $9.19M Mar 24, 2022
FY2020 Dec 31, 2019 $7.36M Mar 30, 2021
FY2019 Dec 31, 2018 $5.94M Mar 30, 2020
FY2018 Dec 31, 2017 $4.25M Apr 1, 2019
FY2017 Dec 31, 2016 $3.09M Apr 2, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $11.38M Mar 30, 2026
FY2025 Dec 31, 2024 $10.63M Mar 30, 2026
FY2025 Dec 31, 2023 $9.75M Mar 30, 2026
FY2024 Dec 31, 2022 $8.57M Mar 24, 2025
FY2023 Dec 31, 2021 $2.66M Mar 28, 2024
FY2022 Dec 31, 2020 $1.15M Mar 27, 2023
FY2021 Dec 31, 2019 ($6.38M) Mar 24, 2022
FY2020 Dec 31, 2018 ($4.53M) Mar 30, 2021
FY2019 Dec 31, 2017 ($2.64M) Mar 30, 2020
FY2018 Dec 31, 2016 ($1.96M) Apr 1, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $5.79M Mar 30, 2026
FY2025 Dec 31, 2024 $5.79M Mar 30, 2026
FY2024 Dec 31, 2023 $5.79M Mar 24, 2025
FY2023 Dec 31, 2022 $5.79M Mar 28, 2024
FY2022 Dec 31, 2021 $2.32M Mar 27, 2023
FY2021 Dec 31, 2020 $2.32M Mar 24, 2022

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($23.51M) Mar 30, 2026
FY2025 Dec 31, 2024 ($21.64M) Mar 30, 2026
FY2024 Dec 31, 2023 ($21.10M) Mar 24, 2025
FY2023 Dec 31, 2022 ($21.61M) Mar 28, 2024
FY2022 Dec 31, 2021 ($21.64M) Mar 27, 2023
FY2021 Dec 31, 2020 ($23.00M) Mar 24, 2022
FY2020 Dec 31, 2019 ($20.80M) Mar 30, 2021
FY2019 Dec 31, 2018 ($18.66M) Mar 30, 2020
FY2018 Dec 31, 2017 ($16.32M) Apr 1, 2019
FY2017 Dec 31, 2016 ($14.95M) Apr 2, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $2.49M Mar 24, 2025
FY2024 Dec 31, 2023 $1.22M Mar 24, 2025
FY2023 Dec 31, 2022 $2.70M Mar 28, 2024
FY2022 Dec 31, 2021 $1.75M Mar 27, 2023
FY2021 Dec 31, 2020 $1.91M Mar 24, 2022
FY2020 Dec 31, 2019 $404.2K Mar 30, 2021
FY2011 Dec 31, 2011 $68 Jan 31, 2012
FY2011 Dec 31, 2010 $1.3K Jan 31, 2012
FY2011 Dec 31, 2009 $305 Jan 31, 2012
FY2011 Oct 2, 1997 $0 Jan 31, 2012

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2022 Dec 31, 2022 $3.34M Mar 27, 2023
FY2021 Dec 31, 2021 $2.00M Mar 24, 2022
FY2020 Dec 31, 2020 $2.84M Mar 30, 2021
FY2019 Dec 31, 2019 $3.54M Mar 30, 2020
FY2018 Dec 31, 2018 $3.54M Apr 1, 2019
FY2017 Dec 31, 2017 $2.45M Apr 2, 2018
FY2016 Dec 31, 2016 $980.3K Mar 30, 2017
FY2014 Dec 27, 2013 $160.0K Mar 31, 2015
FY2014 Nov 12, 2013 $160.0K Mar 31, 2015
FY2014 Feb 4, 2013 $350.0K Mar 31, 2015

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 30, 2026
FY2025 Dec 31, 2024 0 Mar 30, 2026
FY2024 Dec 31, 2023 0 Mar 24, 2025
FY2023 Dec 31, 2022 0 Mar 28, 2024
FY2022 Dec 31, 2021 0 Mar 27, 2023
FY2021 Dec 31, 2020 0 Mar 24, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 30, 2026
FY2025 Dec 31, 2024 0 Mar 30, 2026
FY2024 Dec 31, 2023 0 Mar 24, 2025
FY2023 Dec 31, 2022 0 Mar 28, 2024
FY2022 Dec 31, 2021 0 Mar 27, 2023
FY2021 Dec 31, 2020 0 Mar 24, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 4.48M Mar 30, 2026
FY2025 Dec 31, 2024 4.25M Mar 30, 2026
FY2024 Dec 31, 2023 4.11M Mar 24, 2025
FY2023 Dec 31, 2022 4.07M Mar 28, 2024
FY2022 Dec 31, 2021 2.82M Mar 27, 2023
FY2021 Dec 31, 2020 2.81M Mar 24, 2022
FY2020 Dec 31, 2019 370,497 Mar 30, 2021
FY2019 Dec 31, 2018 354,588 Mar 30, 2020
FY2018 Dec 31, 2017 17.43M Apr 1, 2019
FY2017 Dec 31, 2016 16.82M Apr 2, 2018